Latest Ratios: P/E Ratio -14.6x · EV/EBITDA 6.4x · ROE -9.8%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $161M | $113M | $124M | $202M | $155M | $192M | $89M | $54M | $11M | $22M | $11M |
| Enterprise Value | $267M | $120M | $208M | $283M | $178M | $185M | $88M | $66M | $24M | $32M | $16M |
| P/E Ratio → | -14.60 | — | — | — | 32.08 | — | — | — | 0.75 | — | — |
| P/S Ratio | 0.66 | 0.46 | 0.50 | 0.96 | 1.11 | 1.88 | 1.22 | 0.88 | 0.20 | 0.36 | 0.11 |
| P/B Ratio | 1.41 | 1.01 | 1.16 | 1.82 | 1.95 | 3.28 | 3.15 | 3.74 | 0.73 | 0.31 | 0.12 |
| P/FCF | 6.34 | 4.46 | 4.95 | 6.72 | 9.03 | 14.07 | 9.07 | 7.69 | 1.08 | — | — |
| P/OCF | 4.26 | 3.00 | 3.51 | 5.47 | 5.89 | 10.28 | 9.00 | 6.44 | 1.02 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.49 | 0.84 | 1.34 | 1.27 | 1.80 | 1.20 | 1.07 | 0.44 | 0.52 | 0.17 |
| EV / EBITDA | 6.37 | 2.87 | 4.02 | 6.17 | 6.42 | 11.30 | 6.30 | 11.08 | 3.75 | — | — |
| EV / EBIT | — | — | 404.15 | 57.48 | 35.55 | — | — | — | — | — | — |
| EV / FCF | — | 4.74 | 8.29 | 9.40 | 10.37 | 13.52 | 8.91 | 9.34 | 2.36 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.5% | 97.5% | 72.0% | 72.6% | 76.3% | 72.5% | 52.5% | 72.1% | 69.2% | 70.9% | 50.9% |
| Operating Margin | -1.6% | -1.6% | 0.5% | 2.7% | 3.4% | -1.4% | -0.9% | -7.6% | -9.7% | -20.9% | -42.2% |
| Net Profit Margin | -4.4% | -4.4% | -2.8% | -1.3% | 3.5% | -6.0% | -6.2% | -9.1% | 26.6% | -31.1% | -59.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.8% | -9.8% | -6.2% | -2.9% | 7.0% | -14.2% | -21.4% | -38.0% | 33.5% | -23.5% | -51.7% |
| ROA | -3.9% | -3.9% | -2.7% | -1.5% | 4.0% | -6.8% | -8.0% | -14.0% | 20.6% | -17.9% | -42.4% |
| ROIC | -1.4% | -1.4% | 0.4% | 3.0% | 4.8% | -2.8% | -1.8% | -12.9% | -7.2% | -10.8% | -30.7% |
| ROCE | -1.8% | -1.8% | 0.6% | 4.2% | 5.7% | -2.4% | -1.8% | -19.5% | -9.5% | -13.9% | -35.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.06 | 1.06 | 0.93 | 0.88 | 0.33 | 0.46 | 0.98 | 1.47 | 1.09 | 0.18 | 0.12 |
| Debt / EBITDA | 2.84 | 2.84 | 1.93 | 2.13 | 0.96 | 1.66 | 2.00 | 3.60 | 2.56 | — | — |
| Net Debt / Equity | — | 0.06 | 0.78 | 0.73 | 0.29 | -0.13 | -0.05 | 0.80 | 0.87 | 0.14 | 0.06 |
| Net Debt / EBITDA | 0.17 | 0.17 | 1.62 | 1.76 | 0.83 | -0.46 | -0.11 | 1.96 | 2.04 | — | — |
| Debt / FCF | — | 0.28 | 3.34 | 2.68 | 1.34 | -0.55 | -0.15 | 1.65 | 1.28 | — | — |
| Interest Coverage | -0.57 | -0.57 | 0.12 | 0.76 | 2.46 | -0.73 | -0.34 | -1.42 | -3.60 | -11.42 | -36.00 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | 1.05 | 1.20 | 1.08 | 1.00 | 1.75 | 1.86 | 1.29 | 1.25 | 1.30 | 2.10 |
| Quick Ratio | 0.71 | 0.71 | 0.86 | 0.78 | 0.62 | 1.47 | 1.59 | 1.09 | 0.94 | 0.74 | 1.68 |
| Cash Ratio | 0.17 | 0.17 | 0.27 | 0.28 | 0.20 | 1.06 | 1.20 | 0.54 | 0.24 | 0.19 | 0.35 |
| Asset Turnover | — | 0.80 | 1.00 | 0.86 | 1.06 | 0.94 | 1.02 | 1.47 | 1.44 | 0.60 | 0.86 |
| Inventory Turnover | 0.24 | 0.24 | 3.31 | 3.14 | 2.13 | 3.04 | 5.41 | 4.77 | 4.98 | 2.27 | 3.91 |
| Days Sales Outstanding | — | 51.62 | 43.22 | 44.79 | 42.76 | 42.57 | 45.34 | 55.84 | 64.82 | 45.50 | 69.42 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 3.1% | — | — | — | 133.3% | — | — |
| FCF Yield | 15.8% | 22.4% | 20.2% | 14.9% | 11.1% | 7.1% | 11.0% | 13.0% | 92.8% | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $43M | $43M | $40M | $37M | $30M | $23M | $21M | $20M | $19M | $18M |
Regulatory reimbursement and integration
According to current market data, QIPT trades at an EV/EBITDA of 6.37x, which appears to reflect significant investor skepticism regarding the company's ability to achieve sustainable profitability compared to broader healthcare service peers that often command double-digit multiples in the current market environment.
The low valuation multiple suggests that the market is pricing in a high probability of continued earnings volatility rather than a growth-oriented trajectory. Investors should monitor whether this discount is a structural mispricing of the recurring revenue model or a rational response to the persistent net losses and integration challenges.
Based on reported financial statements, QIPT's ROIC has struggled to maintain positive territory, fluctuating between -0.7% and 0.8% over the last ten quarters, which indicates that the company is currently failing to generate returns that exceed its cost of capital on invested assets.
The inability to consistently compound returns on capital suggests that the aggressive acquisition strategy has yet to yield the expected operational synergies. This trend warrants further investigation into whether the capital deployed for regional roll-ups is being effectively utilized to drive long-term value creation.
As evidenced by the quarterly data, QIPT's cash conversion cycle has shown extreme volatility, ranging from -2295 days to 327 days, which highlights the inherent difficulty in managing collections within the complex and fragmented U.S. healthcare reimbursement environment for durable medical equipment providers.
The erratic nature of the CCC suggests that the company faces significant bottlenecks in converting service delivery into realized cash. This inefficiency appears to be a structural drag on liquidity, necessitating a closer look at the company's billing and accounts receivable management processes.
Based on the most recent filings, QIPT's debt-to-equity ratio spiked to 1.13 in 2026Q1, a significant increase from 0.18 in 2025Q4, indicating that the company's reliance on external financing has intensified just as operational margins have faced renewed downward pressure.
The rising leverage profile, combined with an interest coverage ratio that has dipped below 1.0x in several recent periods, suggests that debt service is becoming increasingly uncomfortable. Investors should monitor the company's ability to refinance existing obligations without further diluting equity or constraining operational flexibility.
Market participants frequently misapply the reported 97.53% gross margin as a proxy for operational health, failing to recognize that this figure likely excludes critical service and delivery costs that are essential to the company's last-mile logistics model in the home medical equipment sector.
By ignoring the classification of delivery labor and equipment depreciation within SG&A, analysts may overestimate the company's underlying unit economics. A more accurate assessment would require adjusting the gross margin to reflect the true cost of service delivery, which would likely reveal a much tighter margin profile.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QIPT stock.
Quipt Home Medical Corp.'s current P/E ratio is -14.6x. The historical average is 16.4x.
Quipt Home Medical Corp.'s current EV/EBITDA is 6.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.0x.
Quipt Home Medical Corp.'s return on equity (ROE) is -9.8%. The historical average is -62.2%.
Based on historical data, Quipt Home Medical Corp. is trading at a P/E of -14.6x. Compare with industry peers and growth rates for a complete picture.
Quipt Home Medical Corp. has 97.5% gross margin and -1.6% operating margin.
Quipt Home Medical Corp.'s Debt/EBITDA ratio is 2.8x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.